Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...

A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...

Pfizer Inc forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit ...

Dec 15 (Reuters) - Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support ...

NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, ...

Under the TCR-antigen data licensing agreement, Adaptive will receive an upfront payment and additional future potential annual licensing fees under this non-exclusive, multi-year data access ...

As the spring saw another surge of coronavirus cases across the country, healthcare officials are urging people to get vaccinated. But some social media posts are spreading false claims that the ...

The FDA said Pfizer had collected more data that was necessary to review. The Food and Drug Administration on Friday postponed its review of Pfizer’s COVID-19 vaccine for kids under 5. “We realized ...

Data from a subanalysis of 30 sera from a Phase 2/3 clinical trial of children 5 through 11 years of age show a 36-fold increase in SARS-CoV-2 Omicron neutralizing titers following a booster (third) ...

Pfizer-BioNTech submitted data to the Food and Drug Administration to clear its Covid-19 vaccine for use in children ages 5 to 11, officials announced Tuesday. The FDA is expected to take at least ...